GLP‑1 market expands
Protein and dairy brands are launching GLP‑1–targeted formats—think protein sodas and nutrient‑dense, on‑the‑go options—positioned to support muscle preservation for drug users and everyday consumers. ( ) New 23andMe analyses suggest genetics may modestly influence GLP‑1 weight‑loss response and side effects, and the FDA plans a summer meeting to consider easing limits on several unapproved peptide injections circulating in wellness circles. ( )
Food and supplement companies are building new products around glucagon-like peptide-1, or GLP-1, drugs as weight-loss treatment reshapes what people want to eat. (nutritioninsight.com) GLP-1 drugs such as semaglutide and tirzepatide reduce appetite, so brands are pushing smaller, nutrient-dense formats with more protein, including protein sodas, ready-to-drink shakes, bars and compact meal options. FrieslandCampina Ingredients, Valio and Roquette told Nutrition Insight they are targeting both GLP-1 users and mainstream consumers. (nutritioninsight.com) Dairy groups are leaning especially hard into the shift because whey and milk proteins are already marketed for muscle maintenance. Fonterra said in March that GLP-1 use is one of its top food-and-nutrition trends for 2026 and forecast stronger demand for protein powders, ready-to-drink shakes and protein-enhanced snacks. (foodingredientsfirst.com) The pitch centers on a basic problem: when people lose weight quickly, they can lose muscle along with fat. Danone’s Oikos launched Oikos Fusion in 2025 as a cultured dairy drink aimed at GLP-1 users, and trade coverage said the product was designed to help offset muscle loss during weight reduction. (nutritionaloutlook.com, vendingmarketwatch.com) The market is expanding just as researchers are trying to explain why patients on the same drugs do not get the same results. A 23andMe Research Institute study published April 8 analyzed 27,885 people who reported using GLP-1 medicines and found genetic variants linked to both weight-loss response and side effects. (23andme.com, nature.com) The strongest efficacy signal in that study was a GLP1R variant associated with an additional 0.76 kilograms of weight loss per copy of the effect allele. The side-effect analysis also found receptor variants tied to nausea and vomiting risk, with one GIPR signal appearing specific to tirzepatide. (nature.com, pharmexec.com) Regulators are also dealing with a parallel GLP-1-adjacent market: unapproved peptide injections sold in wellness and longevity circles. PBS and the Associated Press reported on April 15 that the Food and Drug Administration plans a July advisory meeting on seven peptides to consider whether compounding restrictions should be eased. (pbs.org, ap.org) Those peptides are not approved drugs, and federal officials have previously warned about safety and quality risks in compounded products. Supporters of wider access, including figures in Health Secretary Robert F. Kennedy Jr.’s orbit, have argued the substances should be easier to obtain through pharmacies. (pbs.org, nbcnews.com) Taken together, the food launches, genetics data and FDA review show the GLP-1 economy spreading beyond prescription brands into grocery aisles, ingredient supply chains and a fast-growing gray market. The next marker is July, when the FDA panel is scheduled to weigh those peptide limits in public. (nutritioninsight.com, nature.com, pbs.org)
